http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104557939-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_527ef0ea3f777c30ac252e00259c72eb
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4995
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
filingDate 2014-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edbc109f5d7b431649852845e962b754
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6d2e8a4a1c6a3b6ea68417c3142e41c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77e603f39b04732046faf06b77501cb2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bac1d60246daeaac2babdfc14e546dbc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_880ac8bae5c194aa91a8dbaf90183ea5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4149effb6b1d973dd53d908cc5455b12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_acb86429d8b3299cef9adb1336cf6ada
publicationDate 2015-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-104557939-A
titleOfInvention Hydrochloride salt of pyrrolopyrazine compound and application thereof
abstract The invention belongs to the field of chemical medicine, and relates to a pyrrolopyrazine compound hydrochloride and its application, in particular to a pyrrolopyrazine compound having BCR-ABL kinase inhibitory activity, and a pharmaceutical composition containing the compound and Application of the compound or composition in medicine preparation. The pyrrolopyrazine compound provided by the present invention has a very significant inhibitory effect on various tumor cells, including T315I mutation and drug-resistant leukemia cells, and also exhibits good stability, solubility and oral bioavailability.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106632343-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106632346-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106632146-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106632345-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018068739-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106632347-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106632347-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106632344-A
priorityDate 2013-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103848829-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103664787-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102775411-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467635592
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID428571394
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID76072772
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467391570
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467628227

Total number of triples: 43.